Dr. Chuang is the CEO/founder of CytoArm Co., Ltd. and is a professor at Taipei Medical University, Taiwan. Dr. Chuang is a senior scientist with >20 years of experience in drug R&D and international IP layout, specializing in recombinant protein drug technology, tumor immunology, immune cell therapy, and autoimmune diseases. Dr. Chuang has published >50 SCI research papers, including a number of top international journals (Biomaterials, Journal of Controlled Release, Journal of Advanced Research; impact factor > 10). He also applied for >20 international invention patents and licensed 2 technologies to biotech companies. The next-generation T cell technology platform (Armed-T) created by Dr. Chuang's team has been licensed exclusively to CytoArm Co., Ltd. in 2020. The first Armed-T cell product is ready to initiate an investigator-initiated clinical trial in end-stage untreatable colorectal cancer. Dr. Chuang's achievements in the pharmacy field won the honor of the Ta-You Wu Memorial Award from Taiwan's Ministry of Science and Technology in 2021.